Company’s 36-month beta value is 1.65.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for SYRS is 23.67M, and currently, short sellers hold a 3.86% ratio of that floaft. The average trading volume of SYRS on March 10, 2025 was 3.13M shares.
SYRS) stock’s latest price update
The stock price of Syros Pharmaceuticals Inc (NASDAQ: SYRS) has dropped by -3.87 compared to previous close of 0.09. Despite this, the company has seen a fall of -42.81% in its stock price over the last five trading days. businesswire.com reported 2025-02-28 that CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) and the deregistration of its common stock in order to terminate and suspend the Company’s reporting obligations under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). The Company today.
SYRS’s Market Performance
Syros Pharmaceuticals Inc (SYRS) has experienced a -42.81% fall in stock performance for the past week, with a -53.83% drop in the past month, and a -67.20% drop in the past quarter. The volatility ratio for the week is 25.62%, and the volatility levels for the past 30 days are at 13.17% for SYRS.. The simple moving average for the past 20 days is -44.99% for SYRS’s stock, with a -96.48% simple moving average for the past 200 days.
Analysts’ Opinion of SYRS
Many brokerage firms have already submitted their reports for SYRS stocks, with H.C. Wainwright repeating the rating for SYRS by listing it as a “Buy.” The predicted price for SYRS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on November 04, 2020 of the previous year 2020.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see SYRS reach a price target of $18. The rating they have provided for SYRS stocks is “Buy” according to the report published on September 22nd, 2020.
SYRS Trading at -55.81% from the 50-Day Moving Average
After a stumble in the market that brought SYRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.87% of loss for the given period.
Volatility was left at 13.17%, however, over the last 30 days, the volatility rate increased by 25.62%, as shares sank -54.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -59.05% lower at present.
During the last 5 trading sessions, SYRS fell by -42.81%, which changed the moving average for the period of 200-days by -98.50% in comparison to the 20-day moving average, which settled at $0.1489. In addition, Syros Pharmaceuticals Inc saw -64.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SYRS starting from Flagship Pioneering Fund VII, who proposed sale 1,135,308 shares at the price of $0.24 back on Dec 27 ’24. After this action, Flagship Pioneering Fund VII, now owns shares of Syros Pharmaceuticals Inc, valued at $272,474 using the latest closing price.
AKKARAJU SRINIVAS, the Director of Syros Pharmaceuticals Inc, proposed sale 9,333 shares at $0.25 during a trade that took place back on Dec 30 ’24, which means that AKKARAJU SRINIVAS is holding shares at $2,306 based on the most recent closing price.
Stock Fundamentals for SYRS
Current profitability levels for the company are sitting at:
- -288.92 for the present operating margin
- -2.29 for the gross margin
The net margin for Syros Pharmaceuticals Inc stands at -253.41. The total capital return value is set at -1.97. Equity return is now at value -776.96, with -84.04 for asset returns.
Based on Syros Pharmaceuticals Inc (SYRS), the company’s capital structure generated 1.23 points at debt to capital in total, while cash flow to debt ratio is standing at -1.66. The debt to equity ratio resting at -5.41. The interest coverage ratio of the stock is -20.92.
Currently, EBITDA for the company is -157.19 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 10.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
In a nutshell, Syros Pharmaceuticals Inc (SYRS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
